Endo International PLC Director John Delucca Sells 6,764 Shares (ENDP)
Endo International PLC (NASDAQ:ENDP) Director John Delucca sold 6,764 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $68.83, for a total value of $465,566.12. Following the completion of the sale, the director now directly owns 28,111 shares of the company’s stock, valued at approximately $1,934,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Endo International PLC (NASDAQ:ENDP) traded down 0.61% during mid-day trading on Tuesday, hitting $68.20. 1,580,819 shares of the company’s stock traded hands. Endo International PLC has a 52-week low of $36.17 and a 52-week high of $82.16. The stock’s 50-day moving average is $67.96 and its 200-day moving average is $68.26. The company’s market cap is $10.384 billion.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Thursday, May 1st. The company reported $0.92 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.84 by $0.08. The company had revenue of $595.00 million for the quarter, compared to the consensus estimate of $608.86 million. During the same quarter last year, the company posted $1.09 earnings per share. Endo International PLC’s revenue was down 9.3% compared to the same quarter last year. On average, analysts predict that Endo International PLC will post $3.69 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ENDP shares. Analysts at Wells Fargo & Co. initiated coverage on shares of Endo International PLC in a research note on Tuesday. They set an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Endo International PLC in a research note on Friday, May 2nd. They now have a $70.00 price target on the stock. Finally, analysts at Morgan Stanley upgraded shares of Endo International PLC from an “equal weight” rating to an “overweight” rating in a research note on Friday, May 2nd. They now have a $79.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Endo International PLC presently has a consensus rating of “Hold” and an average price target of $69.00.
Endo International PLC, formerly Endo Health Solutions Inc, incorporated on November 18, 1997, is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.